ORIGINAL RESEARCH article

Front. Genet., 08 January 2021

Sec. Computational Genomics

Volume 11 - 2020 | https://doi.org/10.3389/fgene.2020.581789

Integrated Analysis of Key Genes and Pathways Involved in Fetal Growth Restriction and Their Associations With the Dysregulation of the Maternal Immune System

  • 1. Despartment of Obstetrics and Gynecology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • 2. Ministry of Education-Shanghai Key Laboratory of Children’s Environmental Health, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • 3. Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • 4. Department of Obstetrics and Gynecology, East Hospital, Tongji University School of Medicine, Shanghai, China

  • 5. Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

  • 6. Department of Pharmacology, Zhejiang University Medical School, Hangzhou, China

Abstract

Fetal growth restriction (FGR) is a common pregnancy complication and a risk factor for infant death. Most patients with FGR have preeclampsia, gestational diabetes mellitus, or other etiologies, making it difficult to determine the specific molecular mechanisms underlying FGR. In this study, an integrated analysis was performed using gene expression profiles obtained from Gene Expression Omnibus. Differentially expressed genes (DEGs) between healthy and FGR groups were screened and evaluated by functional enrichment and network analyses. In total, 80 common DEGs (FDR < 0.05) and 17 significant DEGs (FDR < 0.005) were screened. These genes were enriched for functions in immune system dysregulation in the placenta based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Among hub genes identified as candidates for FGR and fetal reprogramming, LEP, GBP5, HLA–DQA1, and CTGF were checked by quantitative polymerase chain reaction, immunohistochemistry, and western blot assays in placental tissues. Immune imbalance could cause hypoxia environment in placenta tissues, thus regulating the fetal-reprogramming. A significant association between CTGF and HIF-1α levels was confirmed in placenta tissues and HTR8 cells under hypoxia. Our results suggest that an immune imbalance in the placenta causes FGR without other complications. We provide the first evidence for roles of CTGF in FGR and show that CTGF may function via HIF-1α-related pathways. Our findings elucidate the pathogenesis of FGR and provide new therapeutic targets.

Introduction

Fetal growth restriction (FGR) is a common pregnancy complication characterized by the failure of the fetus to reach its optimal growth potential. FGR is associated with infant morbidity and mortality () as well as general developmental delay in both intellectual and physical (). Although fetuses with FGR could catch up in early life, they still have a higher risk for chronic metabolic problems as adults, including type II diabetes, insulin resistance, metabolic syndrome, and cardiovascular diseases (; ; ). A number of factors could contribute to the development of FGR, including infections, drug abuse, immune disorders, hypertension, as well as anatomical factors (; ; ; Sebastiani et al., 2018). However, the exact etiology remains elusive. The roles of many transcripts and hormones in the placenta in FGR have been evaluated (; ; ). However, previous studies have included patients with multiples clinical diseases, including preeclampsia, gestational diabetes mellitus, and twin births (; ; ; ), and studies focusing exclusively on patients with FGR are urgently needed to provide insight into the basic pathogenesis.

The placenta plays an important role in the progression of FGR owing to its influence on fetal growth (Zhu et al., 2016). Placental dysfunction is thought to be a predominant cause of FGR, and late FGR (≥32 weeks) presents mild hypoxia with slight deficiencies in placentation (). Generally, a placenta develops in a hypoxic environment associating with vascular remodeling, metabolic changes, oxidative stress, and mitochondrial dysfunction. In early pregnancy, a hypoxic environment stimulating trophoblast cells’ differentiation and vascular remodeling is essential to placentation and fetal development (Soares et al., 2017). Chronic hypoxia contributes to mitochondrial dysfunction as an underlying cause of cellular mechanisms contributing to late FGR (Song et al., 2019). What’s more, hypoxia is also a consequence of placental dysfunction, and low oxygen tension in the cord blood adversely affects fetal development (Soares et al., 2017). Hypoxia-inducible protein HIF-1α, the central factor of the cellular response to hypoxia, is closely related to the development of FGR and fetal-reprogramming (). However, the molecular pathway involving HIF-1α signal in FGR placenta metabolism is not clear, which needs to be further studied and worth exploring.

In this study, significant differentially expressed genes (DEGs) related to FGR were identified by transcriptome-level analyses of placental tissues. Publicly available message RNA (mRNA) profiles were downloaded from Gene Expression Omnibus (GEO) and divided into an FGR group and a healthy control group for the identification of DEGs. Significant DEGs obtained from multiple GEO datasets were further verified by quantitative polymerase chain reaction (qPCR), western blot, and immunohistochemistry (IHC) using placental tissues. Additionally, hypoxia directly or indirectly regulates several genes involved in cell differentiation; correlation analyses were performed for HIF-1α and DEGs to reveal undiscovered gene regulations for interpreting links between the hypoxic environment and fetal development.

Materials and Methods

Data Collection, Processing and Differentially Expressed Gene Screening

For mRNA profiles for placentas in six datasets were downloaded from the GEO repository. GSE98224, GSE75010, GSE100415, and GSE24129 were generated using the same platform, the GPL6244 [HuGene-1_0-st] Affymetrix Human Gene 1.0 ST Array [transcript (gene) version]. GSE10588 and GSE30186 were obtained using GPL2986 ABI Human Genome Survey Microarray Version 2, and GPL10558 was obtained using the Illumina HumanHT-12 V4.0 Expression BeadChip. To minimize interference from multiple conditions, mRNA profiles with descriptions including preeclampsia, large for gestational age, and preterm were excluded. Selected profiles were collected as GSM cohort and assigned to a healthy group or FGR group for subsequent analyses. The clinical characteristics of the GSM cohort are listed in the Supplementary Materials (GSM_profile_information.xls). GSM number is a data number for mRNA array data.

Background correction and quantile normalization of raw data were performed using the SVA package in R (version 3.6.1) (). The limma package in R was utilized to screen DEGs ().1 Probes were annotated and an approximately normal distribution was obtained by log2 transformation. Differentially expressed genes screened with the thresholds FDR < 0.05 and | log2 (Fold Change)| > 0.5 were defined as common DEGs, while thresholds for significant DEGs were FDR < 0.005 and | log2 (Fold Change)| > 0.7. A heatmap and volcano plot were drawn using R.

Bioinformatics Analysis

A Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of common DEGs was performed to discover pathways that were closely associated with FGR using the ‘‘GeneAnswers’’ package.2 A Gene Ontology (GO) enrichment analysis was performed using the ‘‘GOstats’’ package3 to evaluate the functional and biological significance of DEGs. Protein--protein interaction (PPI) network information for common DEGs was obtained using the Search Tool for the Retrieval of Interacting Genes (STRING).4 A weighted gene co-expression network analysis (WGCNA) was performed using the WGCNA R package (), and networks and modules for the top 15% of genes with the largest standard deviations were obtained and visualized. Soft power thresholds (cutoff of powers = 4, scale-free R2 = 0.86) were used to generate modules. The PPI network and WGCNA results were visualized using Cytoscape (version 3.5.1), and a value of P < 0.05 was considered statistically significant referring to the node number.

Study Population

Twenty-seven patients with FGR (without other pregnancy diseases) and 40 healthy pregnant women were recruited from January 2018 to December 2019 at the Obstetrics and Gynecology Hospital of Fudan University and Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. The study was approved by the Ethics Committee of the hospital (approval number: XHEC-D-2020-116). All recruited patients provided signed, informed consent prior to the collection of placental tissues. Initial recruitment for participates was performed on pregnant women at gestational age about 28 weeks, and cases of FGR were primarily screened using fetoplacental Doppler. With the progress of the pregnancy, some FGR cases were relieved. Finally, only the newborn has FGR at delivery donated their placental tissues. Thus placenta donors recruited in our study also belong to SGA. Donors met the following criteria: (1) 20–35 years of age and a gestational age of not less than 37 weeks; (2) singleton pregnancy; (3) non-smoking and non-drinking; and (4) no other pregnancy complications or genetic deficiency now or previously.

Sample Processing

The maternal decidua and fetal chorion on the surface of the placenta were removed and discarded before sampling. Due to the complex and heterogeneous characteristics of the placenta, small pieces of tissues were cut from six different regions of the placenta to avoid the impact of the spatial discrepancy, and each region was 4–6 cm away from the terminal of the umbilical cord. Tissue samples were taken from placentas within 30 min after delivery, fixed in formalin for hematoxylin–eosin (HE) staining and IHC, or frozen immediately in liquid nitrogen and stored at –80°C for RNA extraction. Total RNAs were isolated from placental tissues using an RNeasy Plus Universal Kit (Cat. No. 74134; Qiagen, Hilden, Germany) according to the manufacturer’s instructions. RNA quantity and quality were assessed using an ultraviolet spectrophotometer (ND-1000; NanoDrop Technologies, Wilmington, DE, United States) and an electrophoresis device (Tanon 3500; Tanon, Shanghai, China), respectively.

Quantitative Polymerase Chain Reaction

Total RNA was reverse transcribed using a PrimeScriptTM RT Reagent Kit containing a gDNA eraser (RR047A; Takara, Kusatsu, Japan) according to the manufacturer’s instructions. Briefly, 1 μg total RNA of each sample was reverse transcribed, and cDNA samples were checked about concentrations and pre-diluted to a concentration of about 100 ng/μl for further qPCR assay. The qPCR analysis was performed by following the MIQE guidelines (). Gene expression levels were detected by qPCR using the SYBR-Green PCR Kit (FP205; Tiangen, Beijing, China) and an Applied Biosystems Q7 Real-time PCR instrument (Applied Biosystems, Carlsbad, CA, United States). PCR was conducted under the following cycling conditions: 95°C for 15 min for activation, followed by 40 cycles of 95°C for 10 s, 58°C for 30 s, and 72°C for 30 s. The relative gene expression levels of candidate genes were normalized to the level of GAPDH and calculated by the comparative CT (2–ΔΔCt) method. The sequences of primers are presented in Supplementary Table 1. The amplification efficiencies of the genes ranged from 90 to 115%. The melting curves of tested genes indicated that the amplification was specific (Supplementary Figure 1). Also, genes showed a consistent expression level using the reference gene of either GAPDH or Beta-action (Figure 4C and Supplementary Figure 2).

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

Hematoxylin–Eosin Staining and Immunohistochemistry of Placental Tissues

Placentas maintained in formalin were paraffin-embedded and sliced, followed by histological grading by HE staining. IHC was also performed on sections to verify the results for genes at the protein level, as described by , with a few modifications. Briefly, After blocking with 10% non-immune serum, the sections were incubated with antibody to GBP5 (13220-1-AP; Proteintech, Chicago, IL, United States; 1:150 dilution), HLA–DQA1 (16918-1-AP; Proteintech; 1:100 dilution), and CTGF (23936-1-AP; Proteintech; 1:200 dilution) at room temperature for 2 h, followed by incubation with the secondary antibody (Santa Cruz Biotechnology, United States) for 1 h. After incubation in a streptavidin–peroxidase conjugate, the antibody complexes were visualized with diaminobenzidine tetrahydrochloride chromogen for 10 s. Stained tissue sections were observed using an optical microscope (OlympusTM BX50, Tokyo, Japan).

Cell Culture and Hypoxia Treatment

The trophoblast cell line HTR8/SVneo (HTR8) was provided as a gift by the International Peace Maternity & Child Health Hospital of China Welfare Institute (IPMCH). Cells were verified by STR profiling and cultured in modified RPMI1640 medium (without calcium nitrate, with L-glutamine) (Hyclone, Logan, UT, United States) supplemented with 10% fetal bovine serum (Biowest, Nuaillé, France) and 1% penicillin–streptomycin (Gibco, Carlsbad, CA, United States). Cells were cultured on tissue culture dishes (Thermo Fisher Scientific, Waltham, MA, United States) at 37°C in a 1% O2 incubator to simulate hypoxia, while a condition of 10% O2 has been applied for the routine culture. The HTR8 cell line was used as a model for observing the gene functions of placental extravillous trophoblast in the current study.

Western Blot Analysis

Cells cultured in a hypoxic environment were collected at 0 and 48 h. Then, western blotting was performed to determine the expression level of CTGF. Briefly, cells were washed with cold PBS and lysed in RIPA buffer (Beyotime, Shanghai, China) on ice. Tissues were crumbled before lysing. The supernatant of each sample was collected and quantified by a commercial Bicinchoninic Acid Kit (P0012S; Beyotime Biotechnology, China) for protein determination. Then 20 μg of protein for each sample was separated by 10% SDS/PAGE and transferred to PVDF membranes (Roche, Basel, Switzerland). After blocking in 5% skim milk/TBS–Tween-20 (1%) and incubating with primary antibodies against CTGF (23936-1-AP; Proteintech; 1:1,000 dilution), HIF-1α (20960-1-AP; Proteintech; 1:1,000 dilution), GAPDH (10494-1-AP; Proteintech; 1:20,000 dilution) or β-actin (20536-1-AP; Proteintech; 1:2,000 dilution), membranes were incubated with secondary antibodies and visualized using a chemiluminescence-based detection system (Pierce Biotechnology, Rockford, IL, United States). The intensity of the protein spot was analyzed using densitometry normalized to GAPDH expression.

Statistical Analyses

Data are expressed as mean values and standard deviations. The Student’s t-test was applied to normally distributed data for comparisons between groups, and the Chi-square test was used to evaluate the sex ratio of newborns. A Pearson correlation assay was applied to the microarray data and qPCR to obtain the correlation coefficients for the relationships between the expression level of HIF-1α and those of significant DEGs. A value of P < 0.05 was considered statistically significant.

Results

Identification of DEGs in FGR-Related GSM Profiles

To identify genes associated specifically with FGR without other pregnancy complications, 96 GSM profiles from six GEO datasets were downloaded, screened, and divided into a healthy group (68 healthy subjects) and an FGR group (28 FGR subjects). GSM profiles were successfully normalized (Supplementary Figure 3). A total of 80 common DEGs (FDR < 0.05) were screened and used to generate a heatmap (Supplementary Figure 4), and 17 genes with significant differences (FDR < 0.005) were considered significant DEGs (Table 1). A volcano plot and heat map of significant DEGs are shown in Figures 1A,B, respectively. A list of common DEGs is provided in the Supplementary Materials (DEGs.xls). Clinic characteristics were briefly summarized in Supplementary Table 2.

TABLE 1

Gene nameFDRlogFCDescription
F52.80E−12–0.830Coagulation Factor V
PLAC16.73E−10–0.715Placenta Enriched 1
GSTA32.28E−09–0.726Glutathione S-Transferase Alpha 3
TIMP12.28E−080.740TIMP Metallopeptidase Inhibitor 1
MUC154.45E−08–0.770Mucin 15, Cell Surface Associated
CRH1.27E−071.143Corticotropin Releasing Hormone
AQP19.50E−070.944Aquaporin 1 (Colton Blood Group)
THBS13.76E−060.777Thrombospondin 1
NNAT9.86E−060.844Neuronatin
ACOXL2.81E−05–0.782Acyl-CoA Oxidase Like
CTGF5.08E−050.712Cellular Communication Network Factor 2
GBP50.0002421.030Guanylate Binding Protein 5
FSTL30.0002610.743Follistatin Like 3
LEP0.0003381.506Leptin
KCNK170.000415–0.830Potassium Two Pore Domain Channel Subfamily K Member 17
HLA-DQA10.0007590.950Major Histocompatibility Complex, Class II, DQ Alpha 1
CXCL100.002171.319C–X–C Motif Chemokine Ligand 10

Significant differentially expressed genes (DEGs) in placental tissues of patients with FGR.

Functional Enrichment Analysis of Common DEGs

To investigate the functions and biological pathways involving common DEGs, GO enrichment, and KEGG analyses were performed. The 10 most highly significant GO terms, including biological processes, molecular functions, and cellular components, are summarized in Supplementary Table 3. As shown in Figure 2A, the common DEGs were enriched for various molecular functions (e.g., glycosaminoglycan binding), cellular components (e.g., secretory granule lumen), and biological processes (e.g., skeletal system development). The top 10 enriched KEGG pathways are summarized in Figure 2B and Supplementary Table 4. The common DEGs were mainly involved in immune and inflammatory pathways, such as Staphylococcus aureus infection, asthma, and systemic lupus erythematosus.

Interactome Networks of Genes Generated by WGCNA and PPI

To evaluate interactions among genes related to FGR, a gene co-expression network analysis using WGCNA was performed with the top 15% of genes (1,083) with the largest standard deviations (Figure 3A). Five modules were extracted (shown in different colors in Figure 3). According to an analysis of module–trait relationships (Figure 3B), three modules (shown in turquoise, blue, and yellow) with P-values of <0.05 were identified as significant. Significant DEGs acting as hub genes in significant modules are key candidates for FGR and are listed in Table 3. The blue module shown in Figures 3C,D contained the most hub genes classified as significant DEGs. We defined the term “specific DEGs” for the significant DEGs acting as hubs in modules and networks, indicating their important roles for the pathology of FGR placentas. The module components and gene co-expression networks for the other two significantly modules (i.e., yellow and turquoise) are presented in Supplementary Figure 5.

TABLE 2

VariablesHealthyFGR
Age (years)29.13 ± 3.3929.18 ± 3.82
Gestational age (weeks)39.10 ± 2.6338.04 ± 2.11
Maternal ethnicityChineseChinese
Tissue typePlacentaPlacenta
Previous IUGRNoNo
Previous miscarriageNoNo
Previous hypertensive pregnancyNoNo
Mode proteinuriaNoNo
HELLP diagnosisNoNo
IUGR diagnosisNoYes
Chorioamnionitis diagnosisNoNo
Infant gender (Male/Female)22/1811/16
Infant weight (g)3,340.43 ± 330.282,260.00∗ ± 332.56
Aparg-score 1 min9.55 ± 0.509.48 ± 0.50
Aparg-score 5 min9.88 ± 0.339.48 ± 0.50
Mode of delivery (Cesarean section/Eutocia)19/2111/20

Clinical characteristics of healthy individuals and patients with FGR.

∗P < 0.01.

TABLE 3

Gene nameqPCR-verifiedWGCNA modulesPPI network
TIMP1××○
MUC15דturquoise”×
THBS1××○
CTGF○×○
GBP5○“blue”×
LEP○×○
HLA-DQA1○“blue”×
CXCL10דblue”○

Eight specific DEGs identified as hub genes in the WGCNA or PPI analysis were determined to be key genes for the pathogenesis of FGR.

Protein–protein interaction networks for 80 common DEGs were generated using the STRING database. TIMP1, VWF, EDN1, LEP, THBS1, CXCL10, CYR61, CTGF, ENG, and HLA–DPA1 were significant (P < 0.05) in the PPI networks (Figure 3E). TIMP1, LEP, THBS1, CXCL10, and CTGF identified as specific DEGs are listed in Table 3 and are key genes associated with FGR.

Verification of Significant DEGs in Placental Tissues

Excluding the weight of the fetus, there were no significant differences in age, fetal gender, pregnancy age, and other characteristics between the two groups (Table 2). Quantitative PCR results suggested that GBP5 (P = 0.009, Fold Change = 1.979), LEP (P = 0.002, Fold Change = 2.359), HLA–DQA1 (P = 0.015, Fold Change = 2.404), and CTGF (P = 0.018, Fold Change = 0.529) were significantly related to FGR (Figure 4A). LEP is widely known about it relationship with FGR pathogenesis. GBP5 and HLA–DQA1 are newly defined genes associated with FGR. A previous study has reported an association between CTGF and FGR in serum and placenta (); however, they used a very few idiopathic FGR placenta samples (n < 10). These results were confirmed by IHC analyses of CTGF, GBP5, and HLA–DQA1 in placental tissues (Figure 4B). Five samples in each group were used for validation. The CTGF presented a significant difference (three strong and two moderate in the FGR group, two moderate and three weak in the healthy group). The GBP presented a significant difference (two weak and three moderate in the FGR group, one moderate and four strong in the healthy group). The HLA–DQA1 presented differences but not significant (one weak, three moderate and one strong in the FGR group, three moderate and two strong in the healthy group). The western bot assay further confirmed the up-regulation of CTGF in FGR placental tissues (Figure 4C), which was consistent with the qPCR assay. Pearson correlation analysis on GEO microarray data showed a significant correlation of HIF-1α and CTGF (R = 0.65, P < 0.001), suggesting their cooperation in the pathology of placenta tissues (Figure 4D).

DEGs Associated With the Hypoxic Microenvironment

As determined by qPCR, HIF-1α was significantly up-regulated in FGR placentas (P = 0.001, Fold Change = 0.549, Figure 5A). This result may reflect the more serious hypoxic environment for FGR placentas than for normal placentas. Pearson correlation coefficients were obtained for the relationships between mRNA levels of HIF-1α and significant DEGs. CTGF was significantly associated was HIF-1α (R = 0.702, P < 0.0001, Figure 5B). A western blot assay was conducted using the HTR8 placental trophoblast cell line to confirm the association between CTGF expression and a hypoxic environment. In HTR8 cells cultured in a hypoxic environment, CTGF expression levels were up-regulated (Figure 5C), indicating that it may be involved in HIF-1α-related regulatory pathways under hypoxia.

FIGURE 5

Discussion

The placenta, as a source of peptides and steroid hormones, directly supports fetal development. More importantly, it provides an immune interface between the mother and the fetal allograft (). In this study, we identified 17 significant DEGs (Table 1) and 8 specific hub genes (Table 3) associated with FGR based on an integrated analysis of a GSM cohort. According to GO and KEGG pathway enrichment analyses (Supplementary Tables 3 and 4), the DEGs in FGR placentas were mainly enriched for functions and pathways related to an immunologic imbalance. In addition, the results for newly identified GBP5, HLA–DQA1, and CTGF were verified at the protein (IHC and western blot) and transcript (qPCR) levels, and CTGF was found as a key gene associated with idiopathic FGR. In addition, the expression of CTGF is closely associated with HIF-1α. These results improve our understanding of the pathogenesis of FGR without other pre-gestational diseases and offer potential therapeutic targets for incurable cases. For example, therapies targeting related pathways might relieve the disorder of intracellular metabolism brought by the hypoxia environment and the immunologic imbalance, which were the two main phenotypes of the case of unexplained FGR.

Epidemiological evidence in FGR pregnancies has linked a low birth weight to fetal programming. The differential expression levels of LEP, GBP5, HLA–DQA1, and CTGF were confirmed by qPCR (Figure 4A) and these loci were identified as hub genes in networks and thereby likely play key roles in FGR (Figure 3D,E and Table 3). LEP, the most highly significantly down-regulated gene in FGR placentas, encodes leptin, found in the circulation. Leptin plays a major role in the regulation of energy homeostasis and obesity and is involved in endocrine functions, including the regulation of immune and inflammatory responses, angiogenesis, reproduction, and bone formation (; Steinbrekera and Roghair, 2016). Maternal and fetal leptin levels are correlated with FGR originating from damaged placental function (Zareaan et al., 2017). CTGF, the most significant up-regulated gene, encodes connective tissue growth factor. This factor is related to platelet-derived growth factor and plays roles in chondrocyte proliferation and differentiation as well as cell adhesion (; ). Additionally, as shown in Supplementary Table 3, CTGF contributed to the top 5 GO terms in the molecular function category (i.e., glycosaminoglycan binding, heparin binding, growth factor binding, sulfur compound binding, and integrin binding) and the top 2 GO terms in the biological process category (i.e., response to corticosteroid and skeletal system development), suggesting that it influences the metabolism and immune function in fetal development. Significantly down-regulated GBP5 encodes guanylate binding protein 5, which is related to the innate immune system and the NF-κB pathway. Previous studies have suggested that GBP5 is involved in the mechanism underlying FGR caused by post-natal innate immune alterations. An altered innate immune system is associated with FGR based on the increased susceptibility to infections in the postnatal period (). Additionally, the NF-κB pathway contributes to vascular growth in the developing fetal lung, and the maintenance of endothelial NF-κB activation may be useful in FGR marked by disrupted angiogenesis (). The significantly down-regulated gene HLA–DQA1 encodes a membrane-anchored protein for presenting peptides derived from extracellular proteins. It is mainly expressed in lymphocytes, dendritic cells, and macrophages; these antigen-presenting cells show altered plasticity in FGR placentas (; ; ). In addition, HLA–DQA1 was involved in 8 of the top 10 KEGG pathways (see Supplementary Table 3), indicating that it is closely associated with FGR and fetal programming via immunologic processes.

HIF-1α activates gene transcription in response to changes in oxygen concentrations and accumulates in FGR placentas (Tal et al., 2010). HIF-1α transcription levels were significantly up-regulated in this study. A previous study has demonstrated that maternal inflammation-induced FGR is associated with increased placental HIF-1α (Robb et al., 2017); thus, we hypothesize that the hypoxic microenvironment presenting in most FGR placentas (Figure 5A) could be attributed to immune dysfunction. This inference is supported by the results of our bioinformatics analyses. The hypoxic environment induced oxidative DNA damage in the placenta in FGR (), which may explain the link between the epidemiological characteristics of FGR and fetal reprogramming. In addition, we obtained the first evidence for a correlation between the expression levels of CTGF and HIF-1α. Previous reports have demonstrated that CTGF could be affected by a hypoxic environment (). Our western blot assay using HTR8 cells confirmed the accumulation of CTGF under hypoxia, further suggesting CTGF contributes to hypoxia-related pathways. This finding reveals a common mechanism linking the hypoxic environment to fetal programming as well as the pathogenesis of FGR.

Unlike gestational diabetes mellitus- and preeclampsia-induced FGR, which are mainly explained by metabolic syndrome or hypertensive disorder (; ), our results suggested that the main cause of FGR without other complications is probably abnormal immune functions in the placenta. The novel key genes (GBP5, HLA–DQA1, and CTGF) provide insight into the mechanism underlying FGR development and fetal programming and provide therapeutic targets for improving prognosis. Despite the important discoveries, our study had some limitations. Research revealing biomarkers depends on population-based analyses; however, FGR placentas without other diseases are not easy to collect and thus a larger sample size could improve the discovery of specific FGR-related genes. Furthermore, experiments using cell and animal models are necessary to confirm the newly identified genes and clarify their precise roles.

Statements

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: Six datasets were downloaded from the GEO repository: GSE98224, GSE75010, GSE100415, GSE24129, GSE10588, and GSE30186.

Ethics statement

The studies involving human participants were reviewed and approved by The study was approved by the Ethics Committee of the hospital (approval number: XHEC-D-2020-116). The patients/participants provided their written informed consent to participate in this study.

Author contributions

XW and X-rX: conceptualization, funding acquisition, and review and editing. HZ and YZ: data curation and analysis. HZ and J-rZ: investigation. J-xW: resources. XW: data visualization and writing draft. J-rZ and X-rX: supervision. CT: validation. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the Ministry of Education, Shanghai Key Laboratory of Children’s Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; China Youth Program of National Natural Science Foundation of China (Grant Nos. 81801543 and 81701470), National Science Foundation of China (Grant No. 81871183), and China Postdoctoral Science Foundation (Grant No. 2018M642044).

Acknowledgments

Thanks to Liu Jin, our best friends, for supporting us a lot during our hard-working time.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.581789/full#supplementary-material

References

Summary

Keywords

fetal growth restriction, placenta, immune imbalance, fetal-reprogramming, integration analysis

Citation

Wang X, Zhu H, Lei L, Zhang Y, Tang C, Wu J, Zhou J and Xiao X (2021) Integrated Analysis of Key Genes and Pathways Involved in Fetal Growth Restriction and Their Associations With the Dysregulation of the Maternal Immune System. Front. Genet. 11:581789. doi: 10.3389/fgene.2020.581789

Received

09 July 2020

Accepted

30 November 2020

Published

08 January 2021

Volume

11 - 2020

Edited by

Shibiao Wan, St. Jude Children’s Research Hospital, United States

Reviewed by

Tina Bianco-Miotto, University of Adelaide, Australia; Andrew Lai, Centre for Clinical Research, University of Queensland, Australia

Updates

Copyright

*Correspondence: Xi-rong Xiao, *Correspondence: Jie-ru Zhou,

†These authors have contributed equally to this work

This article was submitted to Computational Genomics, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics